
Authors:
Xiuwei Ma1,2,3, #, Jun Li1,2,3, #, Xiaodong Wang4, #, Wenhao Ma4, Jianhua Wang6, Ruijie Gu1,2,3, Zhiming Zhu4, Yongxia Wang1,2,3, Ying Du4, Juan Xu6, Fang He1,2,3, Xiao Yang1,2,3, Sheng Zhang1,2,3, Lina Zhu1,2,3, Quiuping Li1,2,3, Hui Xiong7, *, Xiaobing Wu4, *, Zhichun Feng1,2,3, *

Affiliations:
1. Senior Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China, 100700
2. National Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing, China, 100700
3. Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China, 100700
4. Genecradle Therapeutics Inc., Beijing, China, 100176
5. Department of Ultrasonics, The Seventh Medical Center of PLA General Hospital, Beijing, China, 100700
6. Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, China, 100700
7. Department of Pediatrics, Peking University First Hospital, Beijing, China, 100034

#: These authors contributed to the work equally.
* Corresponding authors:
Zhichun Feng, zhjfengzc@126.com,
Xiaobing Wu, wuxiaobing@bj-genecradle.com,
Hui Xiong, xh_bjbj@163.com
Abstract

Background: The classic infantile-onset Pompe disease (IOPD) is characterized by cardiac hypertrophy, respiratory insufficiency, and rapidly progressive muscle weakness due to the acid alpha-glucosidase (GAA) deficiency. Enzyme replacement therapy (ERT) is the current approach for IOPD, but it entails several limitations. Aiming to overcome the limited efficiency of ERT, we developed adeno-associated virus (AAV) gene therapy for IOPD patients. Method: One IOPD patient received a single intravenous dose of GC301, a recombinant adeno-associated virus 9 (rAAV9) expressing the human GAA (rAAV9-hGAA). During the follow-up, safety was assessed by the physical examinations, cardiac and laboratory evaluations. GAA activity, the titers of serum antibodies to AAV9 and GAA, and motor development were monitored regularly. Result: The infant showed significant improvements in motor milestones. The GAA enzyme activity increased to the normal range. The cardiac function improved notably. Conclusion: In patient with IOPD, a single intravenous AAV9-hGAA gene therapy improved the clinical outcomes remarkably. The trial is still ongoing, the safety of this gene therapy and the long-term clinical benefit remain to be monitored for months and years to come.

Introduction

Pompe disease, also known as glycogen-storage disease type II or acid maltase deficiency, is a metabolic disorder. It is an autosomal recessive trait characterized by acid alpha-glucosidase (GAA) deficiency leading to lysosomal glycogen storage. The classic infantile-onset Pompe disease (IOPD) is characterized by cardiac hypertrophy, respiratory insufficiency, and rapidly progressive muscle weakness. The infants will die before the age of 1 year without typical treatment. Enzyme replacement therapy (ERT) is the standard of care to treat Pompe disease now. But this treatment entails several limitations, for example, the short drug half-life and an antibody response resulting in reduced efficacy. AAV-associated gene therapy provides a way to prolong the efficacy of GAA enzymatic activity. In this investigator-initiated clinical trial, an AAV-associated gene-drug was used to treat an IOPD infant by intravenous infusion.

Method

The patient

A baby within two months of the birth, the outpatient examination found cyanosis of lips and motor delay. Echocardiography showed hypertrophic cardiomyopathy with increases in interventricular septum thickness in diastole (IVSD) and left ventricular mass (LVM). Genetic tests revealed two compound heterozygous variants, one of which was a maternal frameshift variant (c.258dup, p.Asn87Glnfs*9), and the other was a paternal stop-gain variant (c.2284G > T, p.Glu762*) (Figure S1A), while the GAA activity was 0.14 μmol/L/h (reference value is 1.46 - 20.34 μmol/L/h) (Figure 2A). The infant started ERT immediately after diagnosis. The patient received Myozyme (alfa-glucosidase, 20 mg/kg) treatment twice before administration of GC301 (Figure 1).

GC301

GC301 is a one-single dose gene drug based on rAAV9 in which the codon-optimized human
GAA was transcribed under the control of the constitutive promoter. GMP-grade GC301 was manufactured and supplied by Genecradle Therapeutics Inc.

Study procedure
In this study, the day with GC301 infusion was noted as day 0. The IOPD patient received a single intravenous dose of $1.2 \times 10^{14}$ vector genomes per kilogram bodyweight (vg/kg) of GC301. The day before GC301 delivery, the infant received prophylactic oral prednisolone at 2 mg/kg/day last for two days, then a reduced dose of 1 mg/kg/day on the third day. This dose (1 mg/kg/day) lasted 4 weeks and tapered from the fifth week until the stop. The total prednisolone course was 58 days. Drug safety and efficacy have been observed for 10 weeks post-treatment for the moment. The whole treatment and monitoring process were shown in Figure 1.

Clinical evaluation
According to the study protocol, the safety of GC301 was accessed by the reported adverse events (AE) based on the vital signs, physical examinations, cardiac and laboratory evaluation. GAA activity was monitored every 14 days. The titers of serum antibodies to AAV9 and GAA were detected and analyzed simultaneously. Motor development was assessed by the Hammersmith Infant Neurological Examination (HINE).

Result
Clinical outcomes
The infant showed significant motor improvement with better head-control and reached some other developmental milestones for 4-6 months infant including raising his head when lying face down and rocking on his stomach. The patient was assessed by the HINE before GC301 delivery (the -4th day) and on the 56th Day. The HINE scores were 54 and 69 respectively (Table 1).

GAA enzyme activity
As the main index, GAA activity plays an important role in assessing the clinical benefit from the therapy. The levels of plasma GAA enzyme activity were analyzed during the whole therapeutic process including the ERT and GC301 injection. The GAA activity was lower than the low reference (the value was 1.47 $\mu$mol/L/h, reference is 2.63 - 21.69 $\mu$mol/L/h) before GC301 delivery (the -4th day). The GAA activity began to increase, and the value was 2.90 $\mu$mol/L/h at the end of the 4th week (Figure 2A). Since then, the value had remained within the normal range. The value of GAA activity was 3.64 $\mu$mol/L/h on the 43rd day and 3.1 $\mu$mol/L/h on the 56th day.

Cardiac response
We measured the left ventricular posterior wall thickness (LVPWT), interventricular end septal diastole (IVSD), and left ventricular ejection fraction (EF) by echocardiography. Echo reveals that the left ventricular wall thickness and mass in this infant increased at the time of diagnosis. Cardiac hypertrophy was alleviated after the GC301 delivery. The LVPWT of the infant reduced from 8.7 mm to 7.0 mm on the 7th day and the 73rd day respectively (Figure 2B). The IVSD decreased from 8.5 mm on the 7th day to 6.4 mm on the 73rd day (Figure 2C). The value of EF was 78% on the 73rd day while the value was only 63% on the 7th day (Figure 2D). The left ventricular weight (LVW) declined to 30.20 g on the 59th day from 50.13 g on the 7th day (Figure 2E). The
left ventricular mass index (LVMI) declined from 142.00 g/m².7 on the 7th day to 80.80 g/m².7 on the 59th day (Figure 2F). The more intuitive changes in ventricular wall thickness can be seen in the ultrasound image of day -8 and day 59 (Figure 2G).

Changes in biochemical indexes
The infant serum protein changed followed by GC301 treatment. The serum alanine transaminase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), hydroxybutyrate dehydrogenase (α-HBDH), creatine kinase (CK), creatine kinase-MB (CK-MB), and myoglobin always stayed higher than the high reference value (Table 1). The cardiac troponin I (cTnI) was always kept in the normal ranges. The brain natriuretic peptide (BNP) level decreased into the range of reference values on the 28th day (Table 1). The total cholesterol level increased to the highest on the 28th day (the value is 6.56 mmol/L), then fall into the normal ranges (the value was 4.89 mmol/L on the 56th day and the value was 4.08 mmol/L on the 73rd day) (Table 1). The level of triglyceride showed the same trend as total cholesterol, that is the triglyceride level raised to the highest on the 7th day (the value is 2.46 mmol/L) and then fall into the normal ranges on the 73rd day (the value is 1.63 mmol/L) (Table 1). The level of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) showed similar change trends (Table 1). The level of LDL raised and then fall into the normal ranges. The value of HDL always kept into the normal ranges, but the latest result declined below the low reference value.

Discussion
Pompe disease is a multi-systemic condition with manifestations in the cardiac, skeletal muscles, and nervous system caused by GAA enzymatic deficiency. ERT was approved by the FDA in 2006 and is the only available treatment for Pompe disease by now. Albeit the ERT improved IOPD clinical outcomes, multiple factors including short enzyme turnover time in the blood requiring lifelong usage, low uptake efficiency in skeletal muscle cells, and preferential uptake in the liver leading to enzyme clearance, provide the limited efficiency of ERT. By contrast, a single dose of an AAV-based drug may solve the aforementioned problems and achieve comparable and/or even better clinical effects. In this study, we evaluated the safety and efficacy of GC301, a recombinant adeno-associated virus expressing GAA in a Chinese pediatric patient with IOPD. Especially as we are aware, this is the first gene therapy trial on IOPD patient in the world. To date, no SAE was observed and favorable results suggested GC301 therapeutic efficacy.

GAA enzyme level is a pertinent indicator in assessing the efficacy of gene therapy. In this trial, the GAA activity elevated from the 2nd week after GC301 infusion and raised higher than the lower threshold of clinical reference value on the 4th week and thereafter. We postulated that GC301 could express the transgene GAA rapidly and improve the GAA enzyme level in the blood within two weeks. GAA proteins secreted into the peripheral blood from the targeted tissue cells and those from peripheral blood leucocytes expressing exogenous GAA could contribute to the elevated enzyme level in the blood. However, the anti-GAA antibody level was kept under the detective limits throughout the course, suggesting that the transduced target cells were not eradicated by cellular immunity.
The patient received GC301 infusion 5 days after the second dose of ERT. Peak plasma recombinant human GAA alglucosidase alfa (Myozyme) levels were present directly after infusion, and GAA enzyme levels in the blood declined and cleared within several hours subsequently\(^6,9\). GAA enzyme activity climbed higher than the lower threshold of the normal range (2.63-21.69 \(\mu\)mol/L/h) and reached 3.64 \(\mu\)mol/L/h in our patient on the 6\(^{th}\) week after GC301 infusion. This enzyme activity was even higher than that of his normal mother (2.96 \(\mu\)mol/L/h) who is the heterozygous carrier of GAA gene variant c.258dup (p. Asn87Glnfs*9). Different from the impulsive impact of ERT in the targeted tissue, elevated and sustained GAA enzyme levels in the blood should be attributed to the successful GC301 transduction of target cells and continuous production of therapefic transgene product providing sustained levels in transduced cells and/or secreted levels in plasma for cross-correction.

Among the overall clinical changes, cardiac function improved most significantly. Within 8 weeks after GC301 intravenous infusion, there was an increased EF and a reduction in left ventricular mass suggesting cardiac correction because of GC301. Compared with other gene therapy trials and ERT for IOPD, faster cardiac improvement was observed in this study\(^10-12\). Previous study demonstrated that ten IOPD patients achieved normal LVM (mean Z score = 0.9\(\pm\)0.8) at week 104 after ERT\(^12\), whereas our patient’s LVM Z score was 1.05 at 60\(^{th}\) day post GC301 infusion. In this study, we used the AAV9, which has favorable expression in the heart, at an infusion dose of 1.2\(\times\)10\(^{14}\) vg/kg to treat this infant. GC301 concentration in the blood dropped about 4-logs compared to two hours post-treatment on the 7\(^{th}\) day (1.39E10 VS. 9.63E6). This result is consistent with our PK data in non-human primates (unpublished data). We speculated that the rapid clearance of vector DNA in plasma was associated with the fast transduction of the gene into target cells due to the AAV9 heart and liver tropism\(^13\).

During the follow-up, no severe adverse event (SAE) was observed. We found an asymptomatic elevation on total cholesterol and triglyceride, which only occurred transiently and recovered without any intervention. This observation is different from other AAV gene therapy trials where the clinically significant elevations of liver enzymes were mostly observed in SAE and AE post-treatment\(^14-16\). Increases in serum aminotransferase (ALT and AST) concentrations were noted at the 1\(^{st}\), 4\(^{th}\), 8\(^{th}\) and 10\(^{th}\) weeks post-IV injection of the AAV vector. These elevations were usually associated with the high titers of anti-AAV antibodies\(^16\). The ALT and AST levels at baseline for this patient raised to 3-5 times of upper limit of normal due to the natural course of the disease. However, ALT and AST levels kept relatively stable despite the high titers of the anti-AAV9 antibody (1:12800 in the 8\(^{th}\) week) after GC301 infusion. Other liver function laboratory evaluations, for example, Gamma-glutamyl transferase (GGT) were normal during the trial, indicating that liver function was not affected post-treatment. Although we used a relatively high vector dose, GC301 showed no harm to liver.

In summary, current results on motor development and cardiac response demonstrated that GC301 gene therapy improved the IOPD patient clinical outcomes remarkably. In addition, the patient’s vital signs and laboratory evaluation results showed that the treatment was safe. Although our data so far suggested the safety and efficacy of GC301, the observation period was just 10 weeks after GC301 injection, the trial is still ongoing, and the long-term clinical benefit remains to be
monitored for months and years to come.

**Author Contributions**
Zhichun Feng, Xiaobing Wu and Hui Xiong conceived and designed the clinical trial. Xiuwei Ma, Xiaodong Wang, Ruijie Gu, Jianhua Wang, Hui Xiong, Yongxia Wang, and Wenhao Ma executed the research. Jun Li, Wenhao Ma, Yongxia Wang, Fang He, and Ruijie Gu collected and interpret the data. Xiuwei Ma, Jun Li, Xiaodong Wang, Ying Du, Wenhao Ma, and Zhiming Zhu contributed to the data analysis. Xiuwei Ma, Jun Li, and Xiao Dong Wang drafted the original manuscript, and Xiaobing Wu, Qiuping Li, and Zhichun Feng edited the manuscript. Juan Xu contributed to the vector production quality control. Sheng Zhang, Lina Zhu, and Xiao Yang contributed to patient follow-up and data collection.

**Declaration of interests**
We declare no competing interests.

**Ethics**
This trial was approved by the ethics committee of the seventh medical center of PLA General Hospital (S2022-004-01), and human genetic resource administration of China [2022] SLCJ2122. Clinical trial registered at Chictr.org.cn (ChiCTR2200063229) and Clinicaltrials.gov (NCT05567627). The legal guardian of the infant voluntarily consented to take part in the research study and authorized the use and disclosure of patient’s genetic and clinical information in connection with the study.

**Fund**
This project was supported by the Natural Science Foundation of China Youth Fund (32100640).

**Acknowledgments**
We thank the patient and his parents for participating in this study.

**Reference**
classic infantile Pompe patients with high antibody titers. Orphanet J Rare Dis 2019;14:71.


Figure

Figure 1

[Diagram showing various labels and data points, not transcribed here.]
## Table

**Table 1. The biochemical indexes during the trial**

<table>
<thead>
<tr>
<th></th>
<th>The day of GC301 treatment</th>
<th>Reference value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-4</td>
<td>7</td>
</tr>
<tr>
<td><strong>Basic information</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (month)</td>
<td>3.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>66</td>
<td>68</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>7.6</td>
<td>7.6</td>
</tr>
<tr>
<td><strong>Liver function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>116</td>
<td>127</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>208</td>
<td>240</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>877</td>
<td>860</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>253</td>
<td>200</td>
</tr>
<tr>
<td>GGT (U/L)</td>
<td>19.2</td>
<td>21.3</td>
</tr>
<tr>
<td><strong>Heart function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-HBDH (U/L)</td>
<td>851</td>
<td>875</td>
</tr>
<tr>
<td>CK (U/L)</td>
<td>991</td>
<td>711</td>
</tr>
<tr>
<td>CK-MB (U/L)</td>
<td>42.5</td>
<td>38.0</td>
</tr>
<tr>
<td>Myoglobin (ng/mL)</td>
<td>441</td>
<td>413</td>
</tr>
<tr>
<td>cTnI (ng/mL)</td>
<td>0.15</td>
<td>0.14</td>
</tr>
<tr>
<td>BNP (pg/mL)</td>
<td>404.1</td>
<td>768.7</td>
</tr>
<tr>
<td><strong>Blood lipid profile</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.79</td>
<td>5.57</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td>1</td>
<td>2.46</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>3.70</td>
<td>3.71</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.06</td>
<td>1.74</td>
</tr>
<tr>
<td>HINE</td>
<td>54</td>
<td>69</td>
</tr>
<tr>
<td>AAV genome’s copies/ug gDNA</td>
<td>/</td>
<td>9.63E6</td>
</tr>
<tr>
<td>Anti-AAV9</td>
<td>&lt; 1:100</td>
<td>1:800</td>
</tr>
<tr>
<td>Anti-GAA</td>
<td>&lt; 1:100</td>
<td>&lt; 1:100</td>
</tr>
</tbody>
</table>

Note: In this study, the day of GC301 treatment was noted as day 0.
**Figure legend**

Figure 1. The graphic overview of the clinical trial including the initial time of prednisolone, GC301 administration (Day 0), timepoints of sampling for PK, GAA enzymatic activity check, laboratory and physical tests, etc.

Figure 2. The changes in GAA activity and cardiac function during the course of clinical treatment. The changes of GAA activity(A), LVPWT(B), IVSD(C), EF(D), LVW(E), and LVMi(F) during the whole process of treatment by now. Ultrasound image map of before (day -8) and after (day 59) GC301 treatment was shown in G.

Figure S1. Sanger sequencing revealed compound heterozygous truncating variants c.258dup (p. Asn87Glnfs*9), c.2284G>T (p. Glu762*) in the patient’s GAA gene (A). The pedigree map illustrated the variants in the patient (arrow) and his parents (B).